Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529406 · ClinicalTrials.gov registry record · Phase 4
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
A Phase 4 study of Relapsing Multiple Sclerosis, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT06529406 is a Phase 4 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06529406, a Phase 4 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Conditions Studied
Interventions
- DRUG Ozanimod
Study Locations (3)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Nevada
- Cleveland Clinic - Las Vegas
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06529406
The ClinicalTrials.gov registry entry for NCT06529406 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ozanimod is the first listed.
NCT06529406 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Nevada, Ohio.
Frequently Asked Questions
What is clinical trial NCT06529406 about?
NCT06529406 is a clinical study titled "Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod". A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
What is the current status of trial NCT06529406?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-07-29. Estimated completion is 2029-08-01.
What conditions does trial NCT06529406 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06529406?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT06529406?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529406 being conducted?
This trial has 3 study locations across Colorado, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Ocrevus in Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 4
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.